abstract 8055). 62. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre -Finn C, et al. Metastatic non -small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Annals of Oncology 29 (Supplement 4) : iv192 –iv237, 2018 doi:10.1093/annonc/mdy275. 63. Quoix E, Losconzy G, Fogel F et al. TIME, a phase 2B/3 study evaluating TG4010 in combination with first line therapy in advanced non -small cell lung cancer (NSCLC). Phase 2b results. Ann Oncol 2014; 25: Abs tract 1055 PD. 64. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non -small - OSE2101 Protocol OSE2101C301 Confidential Version n°6.0 Page 86 of 101 02 February 2022 cell lung cancer (LUME -Lung 1): a phase 3, double -blind, rand omised controlled trial. Lancet Oncol.